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Abstract The neutral ceramidase is a key enzyme in the reg-
ulation of cellular ceramide levels. Previously we have reported
that stimulation of rat renal mesangial cells with nitric oxide
(NO) donors leads to an inhibition of neutral ceramidase activ-
ity which is due to increased degradation of the enzyme. This
and the concomitant activation of the sphingomyelinase results
in an ampli¢cation of ceramide levels. Here, we show that the
NO-triggered degradation of neutral ceramidase involves acti-
vation of the ubiquitin/proteasome complex. The speci¢c protea-
some inhibitor lactacystin completely reverses the NO-induced
degradation of ceramidase protein and neutral ceramidase ac-
tivity. As a consequence, the cellular amount of ceramide, which
drastically increases by NO stimulation, is reduced in the pres-
ence of lactacystin. Furthermore, ubiquitinated neutral cerami-
dase accumulates after NO stimulation. In summary, our data
clearly show that the ubiquitin/proteasome complex is an impor-
tant determinant of neutral ceramidase activity and thereby
regulates the availability of ceramide.
) 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide (NO) has become established as a di¡usible
universal messenger mediating cell^cell communication. Renal
mesangial cells exposed to proin£ammatory cytokines express
an inducible NO synthase and produce large amounts of NO
which may contribute to certain forms of glomerulonephritis
[1^3] and other forms of acute and chronic in£ammation [3^
6].
Previously, we have reported that in rat mesangial cells high
levels of NO lead to high amounts of the lipid signaling com-
pound ceramide which is due to a dual action of NO: on the
one hand an activation of the ceramide-generating sphingo-
myelinases and on the other hand an inhibition of the ceram-
ide-degrading enzymes, the ceramidases, which generate
sphingosine and free fatty acids [7^9].
Besides the sphingomyelinases, more recently also the cer-
amide-degrading enzymes have attracted increasing interest.
Although it has been shown that the NO-induced inhibition
of neutral ceramidase is due to proteolytic degradation of the
enzyme, the exact mechanism remains to be established [10].
Over the past years, it has become obvious that a major mech-
anism of selective protein degradation involves the post-trans-
lational modi¢cation of proteins by the small protein ubiqui-
tin, and delivery of these proteins to the proteasome [11^13].
In this study we present evidence that the NO-evoked deg-
radation of neutral ceramidase involves the ubiquitin/protea-
some pathway.
2. Materials and methods
2.1. Materials
Protein A-Sepharose 4B CL was from Amersham Pharmacia Bio-
tech Europe, Freiburg, Germany; [14C]ceramide (speci¢c activity 55
Ci/mol) was from ICN Biomedicals, Eschwege, Germany; (Z)-1-[N-[3-
aminopropyl]-N-[4-(3-aminopropyl-ammonio)butyl]amino]-diazen-1-
ium-1,2-diolate (spermine-NO) was from Alexis, La«ufel¢ngen, Swit-
zerland; the polyclonal rabbit anti-bovine ubiquitin antibody, clasto-
lactacystin L-lactone and lactacystin were from Calbiochem-Novabio-
chem, Schwalbach, Germany; all cell culture nutrients were from In-
vitrogen/Life Technologies, Karlsruhe, Germany; for generation of
a polyclonal anti-neutral ceramidase antibody a synthetic peptide
(ENHKDSGNHWFSTC) based on the N-terminal sequence of the
murine neutral ceramidase was synthesized, coupled to keyhole limpet
hemocyanin, and used to immunize rabbits. The detailed character-
ization is described elsewhere [14].
2.2. Cell culture
Rat mesangial cells were cultivated as described previously [15]. In a
second step, single cells were cloned by limited dilution on 96-well
plates. Clones with apparent mesangial cell morphology were charac-
terized as reported [15] by positive staining for the intermediate ¢la-
ments desmin and vimentin, which is considered to be speci¢c for
myogenic cells, positive staining for Thy 1.1 antigen, and negative
staining for factor VIII-related antigen and cytokeratin, excluding
endothelial and epithelial contaminations, respectively. For the experi-
ments passages 8^20 were used.
2.3. Cell stimulation, immunoprecipitation and Western blot analysis
Con£uent mesangial cells in 60 mm diameter dishes were kept se-
rum-free for 20 h in Dulbecco’s modi¢ed Eagle’s medium containing
0.1 mg/ml of fatty acid-free bovine serum albumin. Thereafter, the
cells were pretreated for 2 h with lactacystin where indicated, before
stimulation with the indicated concentrations or time periods with NO
donors in the absence or presence of lactacystin. To stop the reaction,
the medium was removed and the cells were washed with ice-cold
phosphate-bu¡ered saline (PBS). Cells were then scraped directly
into lysis bu¡er (50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100,
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20 mM L-glycerophosphate, 50 mM sodium £uoride, 1 mM Na3VO4,
10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 1 WM pepstatin A, 1 mM
phenylmethylsulfonyl £uoride) and homogenized by 10 passes through
a 26-gauge needle ¢tted to a 1-ml syringe. The homogenate was cen-
trifuged for 10 min at 14 000Ug and the supernatant taken for protein
determination. 100 Wg of protein was either taken for immunoprecip-
itation and following Western blot analysis or immediately separated
on sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and transferred to nitrocellulose membrane as previously de-
scribed [16] using a polyclonal antibody against the neutral cerami-
dase at a dilution of 1:500 or against ubiquitin at a dilution of 1:1000.
For immunoprecipitation the proteins were incubated overnight at
4‡C with a polyclonal antiserum against the neutral ceramidase or
against ubiquitin at a dilution of 1:100 and 5% fetal calf serum in
lysis bu¡er. Then 100 Wl of a 50% slurry of protein A-Sepharose 4B
CL in PBS was added and the mixture was rotated for 1 h at room
temperature. After centrifugation for 5 min at 3000Ug immunocom-
plexes were washed three times with a low salt bu¡er (50 mM Tris^
HCl, pH 7.5, 150 mM NaCl, 0.2% Triton X-100, 2 mM EDTA, 2 mM
EGTA, 0.1% SDS), three times with a high salt bu¡er (50 mM Tris^
HCl, pH 7.5, 500 mM NaCl, 0.2% Triton X-100, 2 mM EDTA, 2 mM
EGTA, 0.1% SDS) and once with 10 mM Tris. Pellets were boiled for
5 min in Laemmli dissociation bu¡er and subjected to SDS^PAGE
with following Western blot analysis.
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Fig. 1. E¡ect of the proteasome inhibitor lactacystin on NO-mediated neutral ceramidase degradation and activity in renal mesangial cells. Qui-
escent mesangial cells were incubated with a proteasome inhibitor prior to NO treatment and the protein level of neutral ceramidase was de-
tected. A: Cells were stimulated for 24 h with either vehicle (control) or spermine-NO (SP-NO; in mM) in the presence of the proteasome in-
hibitor lactacystin (20 WM; 2 h pretreated) where indicated. B: Cells were incubated for 24 h with either vehicle (control) or spermine-NO (SP-
NO; 0.5 mM) in the presence of the indicated concentrations of lactacystin (in WM; 2 h pretreated). Thereafter, cell lysates containing 100 Wg
of protein were subjected to SDS^PAGE (7% acrylamide gel) and transferred to nitrocellulose membrane. Western blot analyses were per-
formed using an anti-neutral ceramidase antiserum at a dilution of 1:500. The upper panel shows one representative blot. The lower panel
shows the densitometric evaluation of two independent experiments. Data are meansSvariance. C: Cells were incubated for 24 h with either
vehicle (control) or spermine-NO (SP-NO; 0.5 mM) in the presence of the indicated concentrations of lactacystin (in WM; 2 h pretreated).
Thereafter, cell lysates containing 100 Wg of protein were taken for a neutral ceramidase activity assay as described in Section 2. The generated
[14C]sphingosine was separated on thin layer chromatography and evaluated on a Imaging System (Fuji). Results are expressed as percent of
control values and are meansSS.D. (n=4). Neutral ceramidase activity in control cells was 24.0S 1.5 pmol/mg/h.
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2.4. Lipid extraction and ceramide quanti¢cation
Con£uent mesangial cells in 30 mm diameter dishes were stimulated
as indicated in the ¢gure legends. Lipids were extracted [17] and cer-
amide was quantitated by liquid chromatography tandem mass spec-
trometry exactly as previously described [14].
2.5. Neutral ceramidase activity assays
Con£uent mesangial cells were stimulated as described above and
homogenized in lysis bu¡er containing 50 mM Tris, pH 7.5, 0.5%
Triton X-100, 5 mM MgCl2, 1 mM EDTA, 5 mM D-galactonic acid
Q-lactone. Neutral ceramidase activity assays were performed accord-
ing to Mitsutake et al. [18] with some modi¢cations as previously
described [14].
3. Results
To test whether the degradation of neutral ceramidase in-
duced by nitric oxide is mediated through the ubiquitin/pro-
teasome system, we applied lactacystin, a highly selective and
cell-permeable inhibitor of the ubiquitin/proteasome complex.
Analyzing neutral ceramidase protein levels by immunodetec-
tion of mesangial cell lysates reveals that the NO donor sper-
mine-NO leads to a concentration-dependent downregulation
of ceramidase protein, thus con¢rming our previous observa-
tions [10]. This depletion is completely prevented by pretreat-
ment of renal mesangial cells with lactacystin (Fig. 1A) in a
concentration-dependent manner (Fig. 1B). The lower immu-
noreactive band in Fig. 1A is most probably due to unspeci¢c
interaction of the antiserum. To fully block the NO-mediated
e¡ect a concentration of 10 WM lactacystin is required. In
parallel, neutral ceramidase activity measurements reveal
that the NO-mediated reduction of activity is also reverted
by lactacystin (Fig. 1C). A similar e¡ect is obtained with
clasto-lactacystin L-lactone [19], which is the active metabolite
of the natural product lactacystin (data not shown). Consis-
tent with the observed increase of ceramidase protein and
activity in lactacystin-treated mesangial cells, we found a de-
crease of NO-induced ceramide formation in the cells as an-
alyzed by mass spectrometry of extracted lipids (Fig. 2).
To further con¢rm the degradation of ceramidase by the
ubiquitin/proteasome complex in response to nitric oxide, we
investigated a potential ubiquitination of the enzyme in re-
sponse to NO. For this purpose cells were pretreated with
lactacystin in order to block degradation and thereafter stimu-
lated for various time periods with spermine-NO. As shown in
Fig. 3A, immunoprecipitated ceramidase shows a time-depen-
dent increase of ubiquitination when Western blot analysis
was performed using an anti-ubiquitin antibody. Maximal
ubiquitination occurs at 30^120 min. Similar data were ob-
tained when cell extracts were subjected to immunoprecipita-
tion with an anti-ubiquitin antibody followed by Western blot
detection using the anti-ceramidase antibody (Fig. 3B).
4. Discussion
The availability of the signaling molecule ceramide is ¢ne-
tuned by the rate of generation involving sphingomyelinases
and de novo synthesis and the rate of degradation catalyzed
by ceramidases [20]. Whereas sphingomyelinases have at-
tracted interest due to their immediate regulation by an in-
creasing list of ligands such as vitamin D3, UV light, Q-irra-
diation, Fas ligand or doxorubicin, more recently, the neutral
ceramidase has turned out to be a key enzyme in the regula-
tion of intracellular free ceramide concentration particularly
in response to the stress mediator NO and NO-inducing cy-
tokines [7,8,21]. In terms of neutral ceramidase regulation,
NO was found to inhibit neutral ceramidase activity in me-
sangial cells [7]. This e¡ect is due to downregulation of the
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Fig. 2. E¡ect of lactacystin on NO-induced ceramide formation in
mesangial cells. Quiescent mesangial cells were stimulated for 24 h
with either vehicle (control) or spermine-NO (0.5 mM) in the ab-
sence or presence of the indicated concentrations of the proteasome
inhibitor lactacystin (in WM; 2 h pretreated). Thereafter, lipids were
extracted and ceramide was analyzed by tandem mass spectrometry
as described in Section 2. Results are indicated as ng ceramide per
2.5U106 cells and are meansSS.D. (n=4).
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Fig. 3. NO induces ubiquitination of neutral ceramidase in mesan-
gial cells. Quiescent mesangial cells were pretreated for 2 h with 20
WM lactacystin in order to block the proteasome, and then either di-
rectly lysed (control) or treated with 1 mM spermine-NO (SP-NO)
for either 0.5, 1, 2 or 4 h before cell lysis. Thereafter, cells lysates
were taken for immunoprecipitation (IP) using either a polyclonal
antibody against neutral ceramidase followed by Western blot anal-
ysis with an anti-ubiquitin antibody (A) or an anti-ubiquitin anti-
body followed by Western blot (WB) analysis with neutral cerami-
dase antibody (B). Data are representative of two independent
experiments giving similar results.
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protein by increased degradation [10]. In this study we show
that the degradation of neutral ceramidase by NO depends on
the ubiquitin/proteasome pathway. Activation of the protea-
some is a well known, fundamental mechanism for protein
turnover, cell cycle control and signal transduction [11^13].
Conceptually, proteolysis by the ubiquitin/proteasome system
is considered to comprise three steps: identi¢cation of the
protein to be degraded, marking of that protein by attach-
ment of ubiquitin to lysine residues, and delivering it to the
proteasome, a multienzyme protease complex speci¢c for mul-
tiubiquitinated substrates [12] that will degrade it and recycle
ubiquitin. How NO mechanistically activates the proteasome
system is presently unknown. In principle, NO can mediate,
especially under in£ammatory conditions when large amounts
of reactive oxygen species are also generated, protein nitra-
tion, nitrosation and oxidation. In addition, it can form nitro-
syl complexes with metalloproteins [22].
It could be speculated that one ubiquitinating enzyme or a
component of the 26S proteasome complex is modi¢ed at a
critical site by NO. Alternatively, it may be possible that NO
stimulation leads to nitration or nitrosation of neutral ceram-
idase itself, which subsequently may facilitate faster degrada-
tion of the enzyme by the ubiquitin/proteasome. In this con-
text, it is interesting to note that Souza et al. [23] reported an
increased degradation of nitrated proteins by the proteasome
which thus guarantees the removal of nitrated proteins in
vivo. Furthermore, others have shown that oxidative stress
leading to the generation of peroxynitrite increases the degra-
dation of various proteins, including aconitase, by the protea-
some pathway [24]. Peroxynitrite is thought to cause nitration
of target proteins at tyrosine residues [22].
A proposed activation of the proteasome by NO, as sug-
gested by our data from renal mesangial cells and other stud-
ies in K562 leukemia cells and pheochromocytoma PC12 cells,
is contrasted by the ¢nding that in the mouse macrophage cell
line RAW 264.7 NO inhibited the proteasome [25]. That study
showed that lactacystin mimicked the e¡ect of NO to induce
accumulation of the tumor suppressor p53. Furthermore, NO
was shown to trigger deubiquitination of p53.
It is worth noting that RAW 264.7 macrophages and renal
mesangial cells respond di¡erentially to NO stimulation most
likely due to their di¡erent capacities to handle reactive nitro-
gen and oxygen species determined by di¡erences in their
glutathione redox system [9,26,27]. Thus macrophages and
endothelial cells are very sensitive to endogenous NO produc-
tion and readily undergo apoptosis after stimulation with tu-
mor necrosis factor K (TNFK) [28], whereas mesangial cells
are completely resistant to TNFK stimulation, although en-
dogenous NO production takes place [28]. This mesangial cell
protection correlates with high levels of reduced glutathione.
By sequence analysis of neutral ceramidase, several lysine
residues as necessary targets for ubiquitin attachment can be
found in the primary sequence [29]. Further obvious sequence
characteristics, such as a destruction box (D box) composed
of the sequence R-X-X-L-X-X-X-X-N found in the N-termi-
nus of proteins [30] or a KEN box composed of the sequence
K-E-N-X-X-X-N/D located in the N- or C-terminus of the
proteins [31] which are targets for one special class of ubiq-
uitin ligase, the anaphase-promoting complex, are missing.
However, several other ubiquitin ligase complexes have been
identi¢ed.
Further studies have to be done to characterize the involved
ligase complex in detail.
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